Journal article Open Access

Allopurinol pharmacogenetics: assessment of potential clinical usefulness

Zineh, Issam; Mummaneni, Padmaja; Lyndly, Jenna; Amur, Shashi; La Grenade, Lois A.; Chang, Stephen H.; Rogers, Hobart; Pacanowski, Michael A.


DataCite XML Export

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://zenodo.org/record/1236437</identifier>
  <creators>
    <creator>
      <creatorName>Zineh, Issam</creatorName>
      <givenName>Issam</givenName>
      <familyName>Zineh</familyName>
    </creator>
    <creator>
      <creatorName>Mummaneni, Padmaja</creatorName>
      <givenName>Padmaja</givenName>
      <familyName>Mummaneni</familyName>
    </creator>
    <creator>
      <creatorName>Lyndly, Jenna</creatorName>
      <givenName>Jenna</givenName>
      <familyName>Lyndly</familyName>
    </creator>
    <creator>
      <creatorName>Amur, Shashi</creatorName>
      <givenName>Shashi</givenName>
      <familyName>Amur</familyName>
    </creator>
    <creator>
      <creatorName>La Grenade, Lois A.</creatorName>
      <givenName>Lois A.</givenName>
      <familyName>La Grenade</familyName>
    </creator>
    <creator>
      <creatorName>Chang, Stephen H.</creatorName>
      <givenName>Stephen H.</givenName>
      <familyName>Chang</familyName>
    </creator>
    <creator>
      <creatorName>Rogers, Hobart</creatorName>
      <givenName>Hobart</givenName>
      <familyName>Rogers</familyName>
    </creator>
    <creator>
      <creatorName>Pacanowski, Michael A.</creatorName>
      <givenName>Michael A.</givenName>
      <familyName>Pacanowski</familyName>
    </creator>
  </creators>
  <titles>
    <title>Allopurinol pharmacogenetics: assessment of potential clinical usefulness</title>
  </titles>
  <publisher>Zenodo</publisher>
  <publicationYear>2011</publicationYear>
  <dates>
    <date dateType="Issued">2011-12-01</date>
  </dates>
  <resourceType resourceTypeGeneral="JournalArticle"/>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://zenodo.org/record/1236437</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.2217/pgs.11.131</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="https://creativecommons.org/publicdomain/zero/1.0/legalcode">Creative Commons Zero v1.0 Universal</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">Use of pharmacogenetics to inform treatment decisions remains a priority for clinicians, patients and public health agencies. We previously developed a framework for systematically assessing whether pharmacogenetic test information would likely bring value to clinical decision-making and enjoy practical uptake. We applied this tool to allopurinol to determine potential usefulness of HLA genetic information in assessing risk for allopurinol-induced severe cutaneous adverse reactions. We quantified allopurinol use data and the magnitude of adverse event signals using US FDA databases, reviewed reported cases of allopurinol-associated severe cutaneous adverse reactions to assess whether clinical subtypes of patients could be identified, performed pooled analyses of associations between HLA variation and allopurinol-induced severe cutaneous adverse reactions and described considerations in clinical implementation of allopurinol pharmacogenetics.</description>
  </descriptions>
</resource>
256
175
views
downloads
Views 256
Downloads 175
Data volume 113.5 MB
Unique views 246
Unique downloads 168

Share

Cite as